Integrating Practice-Changing Findings to Improve the Care of Patients With Myeloma
Source: Integrating Practice-Changing Findings to Improve the Care of Veterans With Myeloma

Video Module

Tune in to this on-demand Webcast in which Carol Ann Huff, MD, provides expert perspective on the optimal treatment of patients with myeloma, including discussion of recently approved agents and adverse event management.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new diagnosis and staging criteria to determine optimal timing of treatment initiation for patients with myeloma
  • Plan individualized treatment for patients with newly diagnosed myeloma based on patient characteristics and tumor biology/genetics using current guidelines and emerging therapeutic options
  • Integrate recently approved agents into existing treatment strategies for patients with relapsed/refractory myeloma
  • Manage disease- and treatment-related symptoms in patients with myeloma

Topics covered include:

  • Diagnosis and Staging
  • Selecting Appropriate Induction Therapy
  • Autologous Stem Cell Transplantation
  • Duration of Therapy in Multiple Myeloma
  • Optimal Therapy for Transplantation-Ineligible Patients
  • Treatment Options in Relapsed/Refractory Multiple Myeloma
  • Managing Adverse Events
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Program Directors

  • Carol Ann Huff
    MD
    Noopur Raje
    MD

Faculty

  • Carol Ann Huff
    MD

Credit Information

  • Release Date:
    January 25, 2018
  • Expiration Date:
    January 24, 2019
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits
  • Registered Nurses:
    1.2 Nursing contact hours

Information on this Educational Activity

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Program Directors

Carol Ann Huff, MD

Medical Director, Department of Oncology
Associate Professor of Medicine and Oncology
Multiple Myeloma Program
Johns Hopkins University
Baltimore, Maryland

Carol Ann Huff, MD, has disclosed that she has received consulting fees from Adaptive Biotechnologies and Glenmark Pharmaceuticals.

 

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Novartis, Roche, and Takeda Oncology and funds for research support from AstraZeneca.

 

Faculty

Carol Ann Huff, MD


Medical Director, Department of Oncology
Associate Professor of Medicine and Oncology
Multiple Myeloma Program
Johns Hopkins University
Baltimore, Maryland

Carol Ann Huff, MD, has disclosed that she has received consulting fees from Adaptive Biotechnologies and Glenmark Pharmaceuticals.

 

Staff

Terrence Fagan, 


Associate Managing Editor

Terrence Fagan has no real or apparent conflicts of interest to report.
 

Megan K. Murphy, PhD


Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

 

Kristen M. Rosenthal, PhD


Managing Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.

 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles W. Willis, MBA, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower receives consulting fees from Pfizer; Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for physicians, registered nurses, and other healthcare professionals who care for patients with myeloma.


Goal

The goal of this activity is to provide participants with specialized education that addresses the unique needs of veterans with multiple myeloma to improve patient care.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new diagnosis and staging criteria to determine optimal timing of treatment initiation for patients with myeloma
  • Plan individualized treatment for patients with newly diagnosed myeloma based on patient characteristics and tumor biology/genetics using current guidelines and emerging therapeutic options
  • Integrate recently approved agents into existing treatment strategies for patients with relapsed/refractory myeloma
  • Manage disease- and treatment-related symptoms in patients with myeloma
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

1.2 contact hours may be earned for successful completion of this activity.

 

Commercial Support


This program is supported by educational grants from Celgene Corporation, and Takeda Oncology.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 25, 2018, through January 24, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.